| TAH Drug Code | ONAV2 |
|---|---|
| Indications | Non-small cell lung cancer. Metastatic breast cancer. |
| Dosing | As a single agent, first three administrations: 60 mg/m2 once weekly. Beyond the third administration, it is recommended to increase the dose to 80mg/m2 once weekly except in those patients for whom the neutrophil count dropped once < 500/mm3 or 500-1000/mm3 during the first three administrations at 60mg/m2 |
| Hepatic Impairment | Dose adjustment required |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Disease significantly affecting absorption; previous significant surgical resection of stomach or small bowel. Severe hepatic impairment; pregnancy & lactation; patients requiring long-term O2 therapy. Coadministration with meningocococal conjugate vaccine or other live virus vaccines, phenytoin & itraconazole. Pretreatment granulocyte counts <1000/mm3 |
| Adverse Effects | Neutropenia, anemia, thrombocytopenia; nausea & vomiting, diarrhea, anorexia, stomatitis, esophagitis; loss of tendon reflexes, neuromotor disorders, neuroconstipation (rarely progressing to paralytic ileus); alopecia; fatigue, fever, arthralgia including jaw pain, myalgia, pain including pain at tumor site. Vial Ischemic cardiac disease (rare), abnormal liver function tests, dyspnea, bronchospasm, generalized cutaneous reactions (rare). |
| Pregnancy | No (Limited) Human Data – Animal Data Suggest Risk |
| Lactation | Contraindicated |
| More Info | UpToDate |
| TAH Drug Code | ONAV3 |
|---|---|
| Indications | Non-small cell lung cancer. Metastatic breast cancer. |
| Dosing | As a single agent, first three administrations: 60 mg/m2 once weekly. Beyond the third administration, it is recommended to increase the dose to 80mg/m2 once weekly except in those patients for whom the neutrophil count dropped once < 500/mm3 or 500-1000/mm3 during the first three administrations at 60mg/m2. |
| Hepatic Impairment | Dose adjustment required |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Disease significantly affecting absorption; previous significant surgical resection of stomach or small bowel. Severe hepatic impairment; pregnancy & lactation; patients requiring long-term O2 therapy. Coadministration with meningocococal conjugate vaccine or other live virus vaccines, phenytoin & itraconazole. Pretreatment granulocyte counts <1000/mm3 |
| Adverse Effects | Neutropenia, anemia, thrombocytopenia; nausea & vomiting, diarrhea, anorexia, stomatitis, esophagitis; loss of tendon reflexes, neuromotor disorders, neuroconstipation (rarely progressing to paralytic ileus); alopecia; fatigue, fever, arthralgia including jaw pain, myalgia, pain including pain at tumor site. Vial Ischemic cardiac disease (rare), abnormal liver function tests, dyspnea, bronchospasm, generalized cutaneous reactions (rare). |
| Pregnancy | No (Limited) Human Data – Animal Data Suggest Risk |
| Lactation | Contraindicated |
| More Info | UpToDate |